Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | LMNA | P02545 | 4/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 3/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CDC25A | P30304 | 2/20 | 0.50 |
| ▸ | CDC25B | P30305 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18559336 | 0.69 | TSHR (1.00) | LMNATP53SMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL24945385 | 0.67 | MAPT (0.66) | MAPTLMNATP53SMN1; SMN2USP2 | |
| SCHEMBL4206372 | 0.67 | PKM (0.85) | MAPTALDH1A1TSHRHTTKMT2A | |
| SCHEMBL19638020 | 0.66 | ALDH1A1 (0.65) | MAPTSMN1; SMN2ALDH1A1HTTKMT2A | |
| SCHEMBL4206740 | 0.66 | PKM (0.67) | MAPTSMN1; SMN2ALDH1A1TSHRHTT | |
| SCHEMBL19532788 | 0.66 | PKM (0.59) | MAPTLMNATP53SMN1; SMN2ALDH1A1 | |
| SCHEMBL19538744 | 0.66 | LMNA (0.67) | MAPTLMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL12216357 | 0.66 | MAPK1 (0.77) | MAPTLMNASMN1; SMN2ALDH1A1TSHR | |
| SCHEMBL12262621 | 0.66 | PKM (0.80) | MAPTLMNAALDH1A1TSHRKMT2A | |
| SCHEMBL2346035 | 0.65 | ALDH1A1 (0.67) | ALDH1A1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138356-B2 | Chemical inhibitors of inhibitors of differentiation | Angiogeney, Inc. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | ANGIOGENEX | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090226422-A1 | Chemical Inhibitors of Inhibitors of Differentiation | BRAF, MAPK1, RAF1 | MAPT 2323/4885LMNA 2937/4885TP53 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.